When accounting for social determinants of health, Black men have significantly lower prostate cancer-specific mortality than White men
FRIDAY, Jan. 13, 2023 (HealthDay News) — When accounting for social determinants of health (SDOH), Black men with prostate cancer have lower prostate cancer-specific mortality (PCSM) than White men, according to a systematic review and meta-analysis published online Jan. 11 in JAMA Network Open.
Randy A. Vince Jr., M.D., from the University Hospitals Seidman Cancer Center at Case Western Reserve University in Cleveland, and colleagues examined the association of SDOH with PCSM and overall survival among Black and White patients. Data were reviewed from 47 studies with 1,019,908 patients (176,028 Black men and 843,880 White men) who were followed for a median of 66.0 months.
The researchers found that for Black versus White men, there was no significant difference in PCSM or overall survival. A significant race-SDOH interaction was seen for both PCSM and overall survival (regression coefficient, −0.041 and −0.017, respectively). Black patients had significantly higher PCSM than White patients in studies with minimal accounting for SDOH (<5-point score) (hazard ratio, 1.29). PCSM was significantly lower among Black versus White patients in studies with greater accounting for SDOH variables (≥10-point score) (hazard ratio, 0.86).
“These results underscore the importance of accounting for SDOH in racial disparity research,” the authors write. “Addressing inequities in SDOH represents modifiable social factors that require attention to reduce the long-standing disparity in prostate cancer health outcomes.”
Several authors disclosed financial ties to the biopharmaceutical and other industries.
MHT Initiation May Reduce Cardiovascular Risk in Women With Vasomotor Symptoms
Socioeconomic Status Linked to Mortality After Acute Hip Fracture Surgery
Higher Intake of Saturated, Animal Fats May Increase Mortality in Prostate Cancer
Adverse Pathological Features Do Not Predict Benefit of Hormone Therapy in Prostate Cancer
Blinatumomab Improves Event-Free Survival in Children With High-Risk B-Cell ALL
Structured Exercise Should Be Considered as Adjunct Therapy for Cancer
Workplace Psychological Stress Linked to Erectile Function in Young Men
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML